ArticleMolecular and cellular biochemistry2005
Inhibition of secretory phospholipase A(2) enzyme by bilirubin: a new role as endogenous anti-inflammatory molecule.
Article in Molecular and cellular biochemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Total cholesterol and bilirubin levels are associated with neurologic outcomes in patients with out-of-hospital cardiac arrest.Internal and emergency medicine · 2025Observational
- Syringol isolated from Eleusine coracana (L.) Gaertn bran suppresses inflammatory response through the down-regulation of cPLAInflammopharmacology · 2022Article
- Association of Plasma Eicosanoid Levels With Immune, Viral, and Cognitive Outcomes in People With HIV.Neurology · 2022Article
- Unconjugated bilirubin is associated with protection from early-life wheeze and childhood asthma.The Journal of allergy and clinical immunology · 2021Article
- Serum Bilirubin Levels and Extent of Symptomatic Intracranial Atherosclerotic Stenosis in Acute Ischemic Stroke: A Cross-Sectional Study.Frontiers in neurology · 2021Article
- Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases ABiochimica et biophysica acta. Molecular and cell biology of lipids · 2019Review
- Identification of Traditional Chinese Medicine Constitutions and Physiological Indexes Risk Factors in Metabolic Syndrome: A Data Mining Approach.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Synthesis, characterization and bioactivity studies of novel 1,3,4-oxadiazole small molecule that targets basic phospholipase AMolecular and cellular biochemistry · 2017Article
- Chemical modification of ascorbic acid and evaluation of its lipophilic derivatives as inhibitors of secretory phospholipase A(2) with anti-inflammatory activity.Molecular and cellular biochemistry · 2010Article
- Genistein, a potent inhibitor of secretory phospholipase A2: a new insight in down regulation of inflammation.Inflammopharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilirubin is a powerful antioxidant that suppresses the inflammatory process. However its interaction with proinflammatory PLA(2) enzyme is not known. Inhibition of several secretory phospholipase A(2) (sPLA(2)) enzyme activities by bilirubin was studied using (14)C-oleate labeled Escherichia coli as substrate. Bilirubin inhibits purified sPLA(2) enzyme from Vipera russellii and Naja naja venom and partially purified sPLA(2) enzymes from human ascitic fluid, pleural fluid and normal serum in a dose dependent manner. IC(50) values calculated for these enzymes ranges from 1.75 to 10.5 microM. Inflammatory human sPLA(2) enzymes are more sensitive to inhibition by bilirubin than snake venom sPLA(2)s. Inhibition of sPLA(2) activity by bilirubin is independent of calcium concentration. Increasing substrate concentration (upto 180 nmol) did not relieve the inhibition of sPLA(2) by bilirubin and it is irreversible. Bilirubin quenched the relative fluorescence intensity of sPLA(2) in a dose dependent manner in the same concentration range at which in vitro sPLA(2) inhibition was observed. In the presence of bilirubin, apparent shift in the far UV-CD spectra of sPLA(2) was observed, indicating a direct interaction with the enzyme. Inhibition of sPLA(2) induced mouse paw edema by bilirubin confirms its sPLA(2) inhibitory activity in vivo also. These findings indicate that inhibition of sPLA(2) by bilirubin is mediated by direct interaction with the enzyme and bilirubin may act as an endogenous regulator of sPLA(2) enzyme activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.